Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
Date:5/8/2012

he treatment of acute post-operative pain in adults immediately following major abdominal or orthopedic surgery.

General and administrative expenses were $2.1 million for the quarter ended March 31, 2012, compared with $1.6 million for the quarter ended March 31, 2011.  This increase resulted primarily from expenses associated with market research and patent prosecution efforts as well as personnel related expenses, including stock-based compensation, and expenses associated with being a public company.

As of March 31, 2012, AcelRx had cash, cash equivalents and investments of $27.6 million, compared to $35.8 million at December 31, 2011.

"With two of our three planned Phase 3 clinical studies actively enrolling, and with the initiation of the third Phase 3 clinical study planned for the third quarter of 2012, we are looking forward to seeing top-line data from all three Phase 3 clinical trials by late 2012 or early 2013," said Richard King, President and CEO of AcelRx.  Mr. King added, "Based on our dialog with FDA, data from these studies should support an NDA filing, expected in the middle of 2013."

Development Update

  • In March 2012, AcelRx initiated the first of three planned Phase 3 clinical trials, a double-blind, placebo-controlled efficacy and safety trial of adult patients with post-operative pain following open-abdominal surgery.  We expect top-line data for this trial in the second half of 2012.
  • In April 2012, AcelRx initiated a second Phase 3 clinical trial, an open-label active-comparator study comparing ARX-01 to the current standard of care, IV PCA with morphine, in patients with post-operative pain following open-abdominal surgery or major orthopedic surgery.  We expect top-line data for this trial in the second half of 2012.
  • In the third quarter of 2012, AcelRx plans to initiate our third planned Phase 3 clinical trial, a double-blind, placebo-controlled efficacy and
    '/>"/>

  • SOURCE AcelRx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
    2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
    3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
    4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
    5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
    6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
    7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
    8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
    9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
    11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. ... Biotechnology, Inc. for the compounding, packaging and distributing of its ... the United States . ... of compounding naltrexone tablets in various strengths for individual patients ...
    (Date:1/23/2015)... Companies, Inc. (ICBU) has repositioned itself as a holding company ... foothold in the hydroponic, hemp and medical marijuana sectors. By ... the sector, and recently partnering with the Chippewa Tribe Nation ... marijuana, iMD is committing to bring its vision to the ...
    (Date:1/23/2015)... plc (NYSE: MNK ) announced today that ... program. The open-ended authorization permits the company to repurchase ... "Funding additional initiatives and seeking attractive ... to pursue a range of focused growth strategies," said ...
    Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
    ... PLEASANTON, Calif., Nov. 5, 2010 IntegenX, Inc. ... of Human Genetics Meeting announced the launch of ... that automates the construction of DNA fragment libraries ... libraries in approximately 3.5 hours, with the products ...
    ... MASI ) today announced that its management is scheduled ... at The St. Regis Hotel in New York on Tuesday, November ... will be available on the Masimo website at www.masimo.com . ... presentation. About Masimo Masimo (Nasdaq: ...
    Cached Medicine Technology:IntegenX Launches the Apollo 324 System for Automated DNA Library Preparation at the ASHG Meeting 2Masimo to Present at Lazard Capital Markets 7th Annual Healthcare Conference 2
    (Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
    (Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
    (Date:1/22/2015)... is a famous dress online store for wedding dresses and ... collection of wedding dresses , and launches a site-wide women’s ... dress on your big day; the wedding gown is the ... to find the most suitable wedding dress. Now, we are ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 State Forestry ... data management system with support from GEOSYSTEMS, a dedicated ... new solution will leverage Hexagon Geospatial’s ERDAS APOLLO ... data as well as point clouds and documents. This ...
    Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
    ... A new research conducted by Derek Griffiths, Ph.D., professor of ... poor bladder// control is due to the reduced activity of ... reported his findings in a recent issue of the Journal ... imaging (fMRI) technology. , He analyzed the brain ...
    ... is reported to have died after a general practitioner had ... had displayed obvious symptoms of meningitis like a sore neck. ... when her condition deteriorated. Even at the hospital the case ... girl developing rashes. The treatment given to the girl was ...
    ... progress made with regard to a ten-year-old plan to scale ... the poor// and the rich with regard to this however ... 2000, with the establishment of 34 networks for providing better ... to cancer. ,Improvements have been made with ...
    ... researchers which is responsible for over 20% of the ... Arabs.// It was previously believed that genetics had a ... particular mutation is quite rare where people living outside ... responsible for the incidences of Parkinson’s disease beyond this ...
    ... Thomas Sandstrom, Respiratory Medicine and Allergy, University Hospital, Sweden ... to diesel exhaust increased inflammation response in the lungs ... in the airway pathways and openings and when they ... the airway they found a decreased inflammatory cells which ...
    ... Keith Palmer and his team from Southampton General Hospital, ... workers.// The research work is aimed at studying the ... occupational exposure to metal fume. ,Researchers found ... be low compared to the normal persons and an ...
    Cached Medicine News:Health News:Parkinson's Disease Has Genetic Roots 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: